Cytokinetics, Incorporated has started to initiate the Phase IIb study of tirasemtiv (formerly CK-2017357) in people with ALS. Cytokinetics plans to enroll around 400 people with ALS in the clinical trial. Those enrolled will either receive tirasemtiv or the placebo twice daily for three months. The trial will use the revised ALS Functional Rating Scale (ALSFRS-R) to assess the changes from baseline in those receiving either tirasemtiv or the placebo. In April, the FDA granted an orphan drug designation and fast track status to tirasemtiv for the potential treatment of ALS.
Click here to read more.Share this: